[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610910":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":33,"locations":38,"responsibleParty":54,"collaborators":10,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":10,"maxAge":10,"enrollmentInfo":66,"targetDuration":69,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":41,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Henan Cancer Hospital","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Zanubrutinib Combined With Rituximab",null,"Induction treatment:\n\nRituximab, 375mg\u002Fm2, Intravenous administration on day 1 (21 days\u002Fcycle); Zanubrutinib, 160mg twice daily continuous oral administration from 1 to 8 cycles (21 days\u002Fcycle)\n\nMaintenance treatment:\n\nZanubrutinib, 160mg twice daily continuous oral administration for two years (28 days\u002Fcycle)",[13,14],"Drug: Zanubrutinib","Drug: Rituximab",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Zanubrutinib","160mg twice daily continuous oral administration.",[9],[22],"Zanubrutinib pills",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Rituximab","375mg\u002Fm2, Intravenous administration on day 1 of each 3-week cycle",[9],[28],"RiTUXimab Injection",[30],{"name":31,"affiliation":5,"role":32},"Zhihua Yao, M.D. Ph.D","STUDY_DIRECTOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":10,"email":37},"CONTACT","+8613592622292","zlyyyaozhihua1260@zzu.edu.cn",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":10,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Henan Cancer Hospital\u002FThe affiliated Cancer Hospital of ZhengZhou university","RECRUITING","Zhengzhou","Henan","China","CN",{"type":47,"coordinates":48},"Point",[49,50],113.64861,34.75778,{"lat":50,"lon":49},[53],{"name":31,"role":35,"phone":36,"phoneExt":10,"email":37},{"type":55,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Zhihua Yao, PhD","Director","100610910","zanubrutinib-combined-with-rituximab-in-the-treatment-for-patients-with-marginal-zone-lymphoma-100610910",false,"NCT07233720","Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma","A Multicenter Prospective Real-world Study of Zanubrutinib Combined With Rituximab (ZR) in the First-line Treatment for Patients With Marginal Zone Lymphoma (MZL)","Inclusion Criteria:\n\n1. Patients with CD20-positive marginal zone lymphoma diagnosed by histopathology\n2. First-line treatment with the combination regimen of zanubrutinib and rituximab\n3. No receiving systematic treatment before enrollment\n4. Having at least one measurable lesions. Measurable lesions were defined as: the longest diameter of lymph node lesions in CT cross-sectional images \\> 1.5 cm, or the longest diameter of the extranodal lesion is greater than 1.0cm\n5. The patients voluntarily joined this study, signed the informed consent form, had good compliance and cooperated with the follow-up.\n\nExclusion Criteria:\n\n1. Other malignant tumor history or active malignant tumor need be treated\n2. In addition to zanubrutinib and rituximab, other anti-tumor drug treatments were also received simultaneously (except for glucocorticoids aimed at controlling symptoms before formal treatment).","ALL",{"count":67,"type":68},30,"ESTIMATED","24 Months","OBSERVATIONAL","This is a prospective single arm, multi-center, real-world study to observe the efficacy and safety of ZR (Zanubrutinib combined with Rituximab) in the first-line treatment for patients with marginal zone lymphoma (MZL).",[73],"Marginal Zone Lymphoma",[73,18,24],"2025-11-16",{"date":77,"type":78},"2025-11-18","ACTUAL",{"date":77,"type":68},{"date":81,"type":68},"2030-06",{"name":5,"class":6},1]